This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
619 |
4. Check minimum number of eventsNone |
619 |
5. Include endpointsNone |
619 |
6. Filter based on genotype QC (FinnGen only) |
619 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Disorders in reading
based on the number of shared cases.
Similar with more cases:
- Specific development disorders of scholastic skills
- Speech and linguistic disorders, excluding more controls
- Speech and linguistic disorders
- Disorders of psychological development
- Any mental disorder
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 619 | 314 | 305 |
| Unadjusted period prevalence (%) | 0.12 | 0.11 | 0.13 |
| Median age at first event (years) | 14.59 | 17.17 | 11.93 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 534
- Matched controls
- 5341
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F81.0
ICD-10 Finland
Specific reading disorder
8860.8
323.0
494
7
F81.1
ICD-10 Finland
Specific spelling disorder
308.2
79.8
79
*
F90.0
ICD-10 Finland
Disturbance of activity and attention
6.7
45.7
128
240
3150A
ICD-9 Finland
Specific delays in development, Specific reading disorder
+∞
45.5
43
*
N06BA04
ATC
methylphenidate; oral
5.9
31.3
94
187
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.6
30.6
167
601
F80.1
ICD-10 Finland
Expressive language disorder
13.0
29.6
53
45
XA800
NOMESCO Finland
Neuropsychological investigation
5.5
24.9
78
162
N05AH04
ATC
quetiapine; oral
3.1
23.6
155
622
F81.9
ICD-10 Finland
Developmental disorder of scholastic skills, unspecified
12.3
21.1
38
33
F80.2
ICD-10 Finland
Receptive language disorder
10.7
20.7
40
40
F81.3
ICD-10 Finland
Mixed disorder of scholastic skills
10.4
19.4
38
39
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
4.5
19.3
72
179
F81.8
ICD-10 Finland
Other developmental disorders of scholastic skills
13.0
18.3
32
26
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.8
18.2
136
582
3153A
ICD-9 Finland
Specific delays in development, Developmental speech or language disorder[KIELENKEHITYKSEN ERITYISVAIKEUS]
23.8
17.9
25
11
3152A
ICD-9 Finland
Specific delays in development, Other specific learning difficulties
+∞
17.8
17
*
N06AX16
ATC
venlafaxine; oral
3.1
16.9
104
390
N06AX11
ATC
mirtazapine; oral
2.5
16.7
158
769
N06AB04
ATC
citalopram; systemic
2.9
15.8
107
426
N06AX21
ATC
duloxetine; oral
3.8
15.0
66
191
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.9
14.4
97
384
Z13.4
ICD-10 Finland
Special screening examination for certain developmental disorders in childhood
77.1
13.6
15
*
F82
ICD-10 Finland
Specific developmental disorder of motor function
6.9
12.7
31
47
N06AB10
ATC
escitalopram; oral
2.3
12.5
140
723
N06AB03
ATC
fluoxetine; oral
2.9
12.2
77
291
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
12.2
120
584
N05AX08
ATC
risperidone; systemic
3.4
12.0
59
187
N06AB06
ATC
sertraline; oral
2.7
12.0
86
351
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.4
11.8
57
179
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.9
11.1
68
252
IGY99
NOMESCO Finland
Other psychiatric treatment contact
3.8
10.9
46
129
F34.1
ICD-10 Finland
Dysthymia
5.0
10.9
34
71
331
Kela drug reimbursment
Atomoxetine, dexamphetamine, guanfacine and lisdexamphetamine
6.6
10.8
27
43
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
3.7
10.7
46
131
EB1AA
NOMESCO Finland
Tooth X-ray examination
1.8
10.5
289
2091
K02.1
ICD-10 Finland
Caries of dentine
1.9
10.3
369
2905
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
4.0
10.0
40
107
SPAT1283
SPAT
Restricted health certificate
1.9
10.0
196
1258
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
5.6
10.0
28
52
F80.8
ICD-10 Finland
Other developmental disorders of speech and language
10.9
9.8
18
17
S18
ICPC
Laceration/cut
1.9
9.7
171
1052
WYA05
NOMESCO Finland
Emergency visit or other similar visit involving procedures
1.8
9.5
275
1995
N05BA04
ATC
oxazepam; oral
2.2
9.4
105
538
N06AG02
ATC
moclobemide; oral
5.9
9.3
25
44
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
3.5
9.2
43
132
SFA20
NOMESCO Finland
Filling on two surfaces of tooth
1.8
9.2
313
2380
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.7
9.2
64
257
A05
ICPC
Feeling ill
2.3
9.1
90
433
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
2.8
9.1
58
221
F33.00
ICD-10 Finland
Recurrent depression, mild episode without somatic syndrome
5.4
9.0
26
50
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
6.3
8.7
22
36
N03AX09
ATC
lamotrigine; oral
3.2
8.7
44
144
WX110
NOMESCO Finland
Local anesthesy
1.8
8.6
399
3307
F98.8
ICD-10 Finland
Other specified behavioural and emotional disorders with onset usually occurring in childhood and adolescence
6.6
8.6
21
33
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
2.1
8.5
99
516
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.8
8.5
195
1301
F80.9
ICD-10 Finland
Developmental disorder of speech and language, unspecified
6.4
8.4
21
34
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.3
8.4
85
414
J45.9
ICD-10 Finland
Asthma, unspecified
2.2
8.2
89
448
M54.5
ICD-10 Finland
Low back pain
1.8
8.1
156
980
N05CF01
ATC
zopiclone; oral
2.1
8.1
94
487
SFC01
NOMESCO Finland
Adjuvant procedure of filling therapy
2.0
8.1
121
694
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
3.5
8.1
36
107
R06.0
ICD-10 Finland
Dyspnoea
2.2
8.0
89
452
SAA01
NOMESCO Finland
Simple examination of mouth
1.8
8.0
416
3525
IBZ06
NOMESCO Finland
Evaluation concerning developmental neuropsychiatry
6.8
7.9
19
29
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.7
7.9
259
1912
N06AX12
ATC
bupropion; oral
2.6
7.9
57
234
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.3
7.9
39
126
A02BC02
ATC
pantoprazole; systemic
1.7
7.8
215
1508
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
2.7
7.8
53
210
SFA10
NOMESCO Finland
Fillning on one surface of tooth
1.7
7.8
323
2541
WZB00
NOMESCO Finland
Telephone receipt or other advice
1.8
7.8
173
1137
F43.1
ICD-10 Finland
Post-traumatic stress disorder
3.6
7.7
33
95
F40.1
ICD-10 Finland
Social phobias
3.5
7.7
35
106
L12
ICPC
Hand/finger symptom/complaint
2.0
7.7
104
572
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
6.9
7.6
18
27
R03AC03
ATC
terbutaline; inhalant
2.3
7.6
74
354
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.2
7.6
76
368
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.5
7.6
59
253
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
3.5
7.6
34
102
N06BA09
ATC
atomoxetine; oral
10.2
7.6
14
14
ZXA05
NOMESCO Finland
Left side
2.1
7.6
84
427
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.3
7.5
68
315
E66.8
ICD-10 Finland
Other obesity
3.6
7.4
32
93
WX290
NOMESCO Finland
Other blockade of nerve
1.7
7.4
300
2333
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
2.4
7.3
64
290
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.0
7.2
41
145
N06AA12
ATC
doxepin; systemic
5.2
7.2
21
42
EBA05
NOMESCO Finland
Complicated extraction of tooth
2.0
7.2
95
519
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
2.5
7.1
53
222
N05AH03
ATC
olanzapine; systemic
2.6
7.1
50
203
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
3.7
7.0
29
82
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.0
6.9
93
509
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
2.7
6.9
45
175
R03AC02
ATC
salbutamol; inhalant
1.6
6.9
265
2018
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
3.8
6.9
27
73
-
ICD-10 Finland
NA
6.8
6.9
16
24
A03
ICPC
Fever
1.8
6.8
147
951
KMAK
NOMESCO Finland
NA
1.6
6.8
269
2056
ZXA10
NOMESCO Finland
Bilateral
2.1
6.8
81
424
F41.1
ICD-10 Finland
Generalized anxiety disorder
2.5
6.8
53
228
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
6.7
90
496
D06
ICPC
Abdominal pain localized other
2.4
6.7
55
242
N06AX22
ATC
agomelatine; oral
4.1
6.7
24
60
UJF32
NOMESCO Finland
Coloscopy
2.2
6.6
70
349
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
3.7
6.5
26
72
N02BE01
ATC
paracetamol; systemic, rectal
1.6
6.5
358
2971
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
3.4
6.5
29
88
K04.08
ICD-10 Finland
Other specified pulpit
2.4
6.4
56
253
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.1
6.4
76
396
IBA01
NOMESCO Finland
Diagnostic and symptom-mapping evaluation
3.0
6.4
34
117
WX002
NOMESCO Finland
Sedation and analgesia
2.1
6.4
70
354
J01AA02
ATC
doxycycline; systemic
1.6
6.4
260
1994
N03AG01
ATC
valproic acid; systemic, rectal
2.6
6.4
44
176
SPAT1307
SPAT
Psychosocial counselling and guidance
2.0
6.3
80
430
RS210
NOMESCO Finland
NA
11.2
6.3
11
10
WX408
NOMESCO Finland
General anesthesy, balanced
1.7
6.2
130
831
F90.9
ICD-10 Finland
Hyperkinetic disorder, unspecified
4.8
6.2
19
41
SPAT1310
SPAT
Counselling related to known health issue
1.6
6.1
173
1204
J01DB01
ATC
cefalexin; oral
1.7
6.1
403
3473
R02
ICPC
Shortness of breath/dyspnoea
2.2
6.0
57
271
N06BA12
ATC
lisdexamfetamine; oral
6.1
6.0
15
25
F92.9
ICD-10 Finland
Mixed disorder of conduct and emotions, unspecified
6.1
6.0
15
25
P06
ICPC
Sleep disturbance
2.2
6.0
61
299
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
288
1786
2.15
18.90
6.7
5.6
10.0
10.7
umol/l
0.56
273
1670
172
885
2.31
17.78
2.6
1.8
1.6
1.4
%
2.67
158
819
85
311
3.01
17.62
5.3
4.3
—
—
—
0
0
250
1514
2.09
17.01
4.6
3.3
33.4
30.4
u/l
0.26
238
1438
167
865
2.27
16.89
2.2
2.3
156.3
327.3
u/l
1.27
153
832
405
2968
2.05
15.80
7.3
6.1
80.9
83.9
u/l
0.62
388
2786
181
1002
2.14
15.32
3.9
3.0
1.0
1.0
kg/l
0.83
14
139
265
1694
1.99
15.07
11.4
7.5
1.2
1.2
mmol/l
0.48
233
1480
468
3649
2.16
15.04
4.3
3.7
14.3
14.4
pmol/l
0.43
452
3366
246
1560
1.96
14.09
11.0
7.5
1.2
1.2
mmol/l
0.06
227
1454
535
4457
2.48
13.83
15.0
9.2
3.9
3.9
mmol/l
0.89
523
4291
184
1069
2.03
13.43
2.5
2.7
2.4
2.4
mmol/l
0.36
167
977
533
4450
2.42
13.41
15.0
9.2
139.7
139.6
mmol/l
1.01
522
4305
227
1423
1.94
13.28
7.2
5.6
38.1
38.1
g/l
0.05
212
1334
374
2784
1.87
12.56
12.2
9.1
4.0
3.8
e9/l
0.80
329
2418
475
3838
2.02
12.25
3.7
2.7
5.7
5.5
mmol/l
1.56
451
3556
122
632
2.16
11.95
3.6
2.9
0.9
0.6
e6/l
0.43
72
333
186
1134
1.92
11.54
4.0
3.7
9.1
9.1
mmol/l
0.07
173
1010
509
4256
2.10
11.37
5.0
4.1
1.8
2.0
mu/l
0.51
489
4010
190
1177
1.89
11.18
1.7
1.5
97.1
97.1
pmol/l
0.01
106
642
45
149
3.18
11.00
1.7
3.0
66.6
66.3
g/l
0.08
39
141
208
1338
1.84
10.79
4.1
3.4
—
—
—
0
0
176
1082
1.88
10.51
4.1
3.3
0.2
0.2
e6/l
0.15
135
802
396
3121
1.75
9.79
4.5
3.7
8.6
7.4
mm/h
1.44
373
2906
247
1757
1.68
8.57
3.0
2.7
62.7
69.0
nmol/l
3.69
234
1650
58
252
2.44
8.52
7.6
11.4
0.7
0.4
mmol/l
0.20
39
198
43
161
2.80
8.50
1.7
1.9
6.1
6.7
ug/l
0.07
37
146
553
4911
2.18
8.45
14.4
9.5
21.7
20.5
mg/l
0.38
453
3594
308
2327
1.64
8.39
6.9
4.9
6.2
6.3
mmol/l
0.18
283
2084
291
2169
1.64
8.35
3.6
3.0
0.0
0.0
estimate
0.00
30
440
78
390
2.14
8.24
1.6
1.6
1099.7
1101.3
nmol/l
0.01
64
312
415
3417
1.65
7.72
4.7
3.5
37.2
37.2
mmol/mol
0.02
398
3251
558
5019
2.13
7.49
11.6
7.7
33.6
28.2
u/l
0.91
546
4860
70
349
2.13
7.44
2.2
1.7
—
—
—
0
0
286
2175
1.59
7.23
4.9
4.1
0.0
0.0
estimate
0.50
36
465
167
1121
1.67
6.98
3.0
2.7
54.8
56.0
u/l
0.12
152
1043
69
351
2.09
6.97
2.2
1.7
—
—
—
0
0
82
445
1.97
6.93
2.2
2.2
2.4
2.4
mmol/l
0.39
68
377
287
2201
1.57
6.89
3.7
3.0
0.0
0.0
estimate
0.00
36
445
153
1032
1.64
6.19
2.2
2.7
2.4
2.6
mg/l
0.54
136
899
103
628
1.77
6.04
4.1
3.0
3.5
3.3
e6/l
0.04
55
331
93
550
1.81
6.04
10.4
6.6
0.8
0.8
mmol/l
0.06
87
525
509
4526
1.70
5.97
18.9
12.0
13.3
13.1
%
1.94
503
4444
92
548
1.80
5.83
1.4
1.5
456.2
13646060.4
pmol/l
0.50
81
491
11
20
5.58
5.82
5.4
4.1
—
—
—
0
0
136
908
1.64
5.69
3.2
2.6
0.8
1.0
mg/l
0.38
91
616
39
175
2.31
5.38
1.4
1.3
—
—
—
0
0
88
531
1.77
5.33
4.4
4.1
29.3
30.2
s
0.85
88
522
144
1003
1.57
5.00
2.5
2.2
—
—
—
0
0
449
3937
1.51
4.93
9.8
7.3
105.2
103.2
ml/min/173m2
1.13
342
2994
44
216
2.12
4.90
13.7
9.5
1.0
1.2
inr
—
6
51
71
412
1.82
4.90
2.5
2.5
25.9
155.4
u/l
0.56
63
344
47
237
2.06
4.89
2.0
2.1
86.3
87.2
ml/min/173m2
0.05
13
82
100
643
1.66
4.81
3.6
4.6
11.0
13.4
mg/mmol
0.23
73
466
110
730
1.62
4.67
4.8
2.8
4389.1
4285.4
umol/l
0.01
101
672
142
1003
1.54
4.61
2.4
2.3
60.0
33.9
ng/l
0.35
52
396
81
499
1.72
4.56
2.1
1.8
—
—
—
0
0
465
4141
1.49
4.43
3.8
3.0
2.9
2.8
mmol/l
0.20
447
3922
251
2001
1.43
4.39
4.5
3.9
—
—
—
0
0
43
220
2.03
4.32
2.8
1.7
—
—
—
0
0
10
22
4.60
4.31
1.6
1.3
—
—
—
0
0
74
454
1.72
4.23
2.8
2.6
20.6
24.9
%
1.91
65
400
443
3924
1.45
4.20
3.3
2.7
1.3
1.2
mmol/l
1.93
423
3737
94
623
1.60
4.00
1.4
1.3
21.0
18.9
nmol/l
0.74
83
546
210
1645
1.42
3.96
1.6
1.5
1.6
2.1
u/ml
0.23
48
392
392
3429
1.39
3.75
4.6
3.1
46.0
32.7
u/l
0.86
375
3299
101
694
1.54
3.68
1.3
1.2
19.0
20.4
iu/ml
0.08
26
181
74
472
1.64
3.67
14.6
6.9
0.9
1.5
mmol/l
0.63
59
381
459
4139
1.42
3.57
3.7
3.0
4.6
4.6
mmol/l
0.79
444
3952
150
1126
1.44
3.53
4.1
3.2
0.0
0.0
estimate
1.08
33
450
70
445
1.65
3.52
3.8
4.5
237.6
813.2
ng/l
0.96
54
339
26
119
2.24
3.49
1.8
1.8
—
—
—
0
0
454
4109
1.39
3.28
3.6
2.9
1.3
1.4
mmol/l
6.92
439
3915
13
43
3.07
3.26
1.3
1.1
—
—
—
0
0
13
43
3.07
3.26
1.3
1.1
—
—
—
0
0
13
43
3.07
3.26
1.3
1.1
—
—
—
0
0
13
43
3.07
3.26
1.3
1.1
—
—
—
0
0
32
164
2.00
3.25
11.1
12.1
1.6
1.4
%
0.24
32
164
16
60
2.71
3.25
1.0
1.1
—
—
—
0
0
9
19
4.79
3.25
2.8
2.6
9.4
17.3
umol/l
—
9
19
84
572
1.54
3.19
3.4
2.8
833.1
931.2
ng/l
0.07
48
285
128
950
1.44
3.18
1.6
1.6
1.7
1.4
mmol/l
1.99
118
851
13
44
3.00
3.15
1.3
1.1
—
—
—
0
0
73
484
1.58
3.11
8.5
3.9
6.5
7.1
umol/l
0.11
61
399
285
2416
1.33
3.10
3.7
3.0
66.6
71.1
ug/l
0.33
271
2278
12
40
3.04
2.98
1.3
1.1
—
—
—
0
0
31
163
1.95
2.95
11.4
12.2
0.7
0.7
%
0.32
31
163
12
41
2.96
2.87
2.8
1.6
—
—
—
0
0
17
71
2.43
2.82
5.5
5.7
1.4
1.4
mmol/l
0.04
17
71
8
18
4.49
2.80
7.0
6.3
—
—
—
0
0
28
146
1.96
2.74
1.2
1.2
—
—
—
0
0
14
54
2.63
2.72
2.3
2.2
—
—
—
0
0
9
24
3.79
2.68
1.3
1.5
—
—
—
0
0
41
244
1.73
2.67
1.7
1.6
317.0
181.1
u/ml
2.16
27
129
30
162
1.90
2.67
11.7
12.3
93.6
94.6
%
0.47
30
162
28
148
1.93
2.65
1.2
1.2
—
—
—
0
0
15
61
2.50
2.63
1.0
1.0
—
—
—
0
0
18
80
2.29
2.63
1.7
1.3
—
—
—
0
0
201
1666
1.31
2.44
3.6
2.9
—
—
—
0
0
59
396
1.54
2.42
1.4
1.6
256.5
293.1
mu/l
0.90
51
351
6
12
5.04
2.40
4.0
5.4
—
—
—
0
0
13
52
2.53
2.37
1.5
1.7
—
—
—
0
0
595
5760
1.85
2.34
22.3
13.8
139.0
138.7
g/l
0.21
590
5684
133
1045
1.35
2.33
3.5
2.1
—
—
—
0
0
40
247
1.66
2.31
1.7
1.5
—
—
—
0
0
18
85
2.15
2.31
1.4
1.3
—
—
—
0
0
18
85
2.15
2.31
1.4
1.3
—
—
—
0
0
6
13
4.65
2.27
3.2
3.5
154.2
134.8
ug/l
—
6
13
59
402
1.52
2.27
1.9
1.8
—
—
—
0
0
47
304
1.59
2.27
1.5
1.4
—
—
—
0
0
25
136
1.87
2.21
5.4
4.0
24.6
27.2
nmol/l
0.57
25
131
8
24
3.36
2.18
2.3
2.6
1611.5
703.8
u/ml
—
8
24
32
190
1.72
2.14
1.5
1.3
—
—
—
0
0
15
68
2.24
2.12
6.3
2.9
9.3
10.7
%
—
10
53
14
63
2.25
2.02
1.0
1.1
—
—
—
0
0
7
21
3.36
1.97
1.9
1.3
—
—
—
0
0
14
64
2.21
1.95
6.6
3.0
—
—
—
0
0
8
27
2.99
1.94
1.5
1.1
—
—
—
0
0
72
529
1.41
1.91
3.0
2.5
4991.2
4222.7
u/l
0.10
22
224
212
1816
1.25
1.91
2.8
2.4
—
—
—
0
0
52
360
1.49
1.89
1.9
1.9
5.5
6.8
u/l
0.92
39
282
16
79
2.05
1.87
1.3
1.2
—
—
—
0
0
16
80
2.03
1.81
1.3
1.2
—
1.1
—
0
7
228
1981
1.24
1.79
2.2
1.8
—
—
—
0
0
63
462
1.40
1.71
1.1
1.1
—
—
—
0
0
32
204
1.60
1.69
8.5
5.6
3.2
3.2
g/l
0.06
32
197
195
1677
1.24
1.66
2.7
2.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
62
2.12
1.66
10.2
13.6
0.3
0.4
u/ml
—
7
36
31
197
1.60
1.66
2.6
1.5
107.9
107.3
u/ml
—
8
24
7
25
2.82
1.65
4.9
7.8
—
—
—
0
0
8
32
2.52
1.60
1.4
1.1
—
—
—
0
0
86
671
1.33
1.60
1.3
1.2
1.2
6.8
u/ml
3.33
29
274
5
15
3.35
1.52
3.2
4.0
—
—
—
0
0
31
202
1.56
1.51
4.6
3.1
7.8
7.4
umol/l
0.05
22
158
46
634
0.70
1.50
1.2
1.4
—
—
—
0
0
34
228
1.52
1.47
1.3
1.4
—
—
—
0
0
51
373
1.40
1.43
10.0
5.7
5.2
5.1
kpa
0.26
46
350
12
60
2.02
1.39
1.0
1.1
—
—
—
0
0
24
151
1.61
1.36
1.6
1.7
—
—
—
0
0
56
420
1.37
1.36
1.3
1.3
—
—
—
0
0
64
496
1.32
1.27
2.8
2.3
11.1
13.0
nmol/l
1.27
57
450
23
350
0.64
1.27
1.7
1.8
—
—
—
0
0
49
365
1.37
1.26
10.2
5.7
1.6
1.1
mmol/l
0.84
31
268
25
165
1.54
1.19
1.6
1.6
1.2
1.2
g/l
0.38
25
153
25
169
1.50
1.09
2.3
2.0
39.6
40.1
u/l
0.04
20
159
47
358
1.34
1.07
1.9
1.8
6.7
12.3
iu/l
3.37
30
274
17
105
1.64
1.07
1.2
1.2
—
2.6
—
0
11
24
162
1.50
1.05
1.7
1.6
0.3
0.2
g/l
0.45
24
153
18
114
1.60
1.03
1.2
1.2
—
6.3
—
0
5
5
22
2.28
1.03
1.4
2.7
15.2
19.2
ug/l
—
5
22
7
34
2.07
1.03
6.3
3.9
22.1
26.4
umol/l
—
7
34
17
107
1.61
1.00
1.2
1.2
—
7.6
—
0
15
7
35
2.01
1.00
2.1
2.1
0.2
0.1
nmol/l
—
7
27
17
108
1.59
0.97
1.2
1.2
—
—
—
0
0
58
463
1.28
0.97
2.3
2.6
0.9
1.3
ug/l
2.36
53
428
9
50
1.81
0.97
1.2
1.5
—
—
—
0
0
34
251
1.38
0.96
1.9
1.8
—
—
—
0
0
23
158
1.47
0.95
2.1
1.9
219.8
225.6
pmol/l
0.05
23
151
11
62
1.79
0.94
1.6
2.6
—
—
—
0
0
45
350
1.31
0.92
2.3
2.7
34.4
21.8
%
—
7
80
528
5123
1.21
0.91
18.9
10.5
41.0
41.0
%
0.12
435
4425
23
162
1.44
0.85
1.7
1.6
—
—
—
0
0
6
31
1.94
0.84
2.2
1.2
—
—
—
0
0
10
57
1.77
0.84
2.0
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
33
1.83
0.79
1.5
1.1
—
—
—
0
0
0
26
0.00
0.78
0.0
2.2
—
7.5
—
0
20
9
53
1.71
0.75
1.6
1.6
—
—
—
0
0
7
38
1.85
0.73
1.1
1.3
—
—
—
0
0
7
41
1.72
0.70
1.6
1.8
—
—
—
0
0
98
861
1.16
0.68
3.4
1.9
—
—
—
0
0
5
28
1.79
0.66
1.4
3.7
—
—
—
0
0
5
28
1.79
0.66
1.4
3.7
—
—
—
0
0
55
460
1.21
0.66
1.2
1.3
94.2
139.1
iu/ml
0.41
14
167
0
22
0.00
0.59
0.0
1.3
—
2.5
—
0
8
11
72
1.54
0.59
2.8
1.7
—
—
—
0
0
11
72
1.54
0.59
3.0
2.0
1.0
5.0
ug/l
0.55
11
67
10
64
1.57
0.59
2.3
2.3
—
—
—
0
0
32
256
1.26
0.58
1.2
1.2
6.6
1.6
u/ml
0.78
19
135
6
35
1.72
0.58
1.0
1.0
—
—
—
0
0
18
132
1.37
0.57
1.5
2.0
—
—
—
0
0
6
36
1.67
0.57
3.0
1.6
—
—
—
0
0
10
66
1.52
0.53
1.7
1.9
—
—
—
0
0
27
336
0.79
0.52
3.0
2.7
31.0
31.1
%
0.01
21
244
6
41
1.47
0.50
1.0
1.1
272.2
294.1
mg/l
—
6
34
23
182
1.27
0.47
1.2
1.2
—
—
—
0
0
12
165
0.72
0.47
1.4
2.1
20.9
28.7
u/ml
0.64
12
156
7
48
1.46
0.47
1.0
1.1
—
—
—
0
0
7
50
1.40
0.45
1.6
1.4
—
—
—
0
0
15
113
1.34
0.43
1.3
1.1
5.0
2.7
u/ml
—
8
53
5
32
1.57
0.42
1.0
1.2
142.0
227.2
iu/ml
—
5
32
8
57
1.41
0.42
3.3
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
2.8
—
1.7
—
0
15
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
17
0.00
0.40
0.0
1.5
—
—
—
0
0
17
132
1.30
0.40
1.1
1.1
—
9.7
—
0
10
0
18
0.00
0.40
0.0
2.4
—
—
—
0
0
58
516
1.14
0.38
1.3
1.4
—
—
—
0
0
30
353
0.84
0.37
1.9
1.7
—
—
—
0
0
9
70
1.29
0.36
6.0
1.9
—
—
—
0
0
11
81
1.36
0.36
2.1
1.5
—
—
—
0
0
19
154
1.24
0.34
1.6
1.6
—
—
—
0
0
487
4953
0.92
0.34
4.2
3.9
—
—
—
0
0
33
381
0.86
0.33
1.5
1.6
—
—
—
0
0
13
101
1.29
0.32
2.8
1.7
—
—
—
0
0
28
241
1.17
0.29
2.1
1.8
30.6
35.7
nmol/l
0.65
28
236
8
110
0.72
0.29
2.1
2.0
—
—
—
0
0
16
130
1.24
0.29
3.3
4.1
2.6
7.8
ug/l
—
9
94
9
120
0.75
0.27
2.1
2.1
—
—
—
0
0
13
104
1.26
0.26
1.5
1.4
14.4
12.6
u/l
0.09
13
91
8
67
1.20
0.26
1.1
1.1
—
—
—
0
0
11
88
1.25
0.22
1.2
1.4
2.6
3.5
u/ml
—
5
44
17
144
1.19
0.22
1.2
1.0
0.1
0.6
u/ml
—
6
42
5
42
1.19
0.21
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
8.1
—
0
13
6
48
1.25
0.20
2.2
1.1
—
—
—
0
0
6
51
1.18
0.19
1.2
1.5
—
—
—
0
0
7
58
1.21
0.18
4.0
3.4
7.4
53.4
u/ml
—
7
45
20
177
1.13
0.16
1.4
1.3
2.9
4.1
ug/l
0.93
20
165
8
72
1.11
0.16
1.9
1.5
—
—
—
0
0
12
102
1.18
0.15
2.7
1.7
—
—
—
0
0
10
84
1.19
0.14
1.7
1.3
—
—
—
0
0
24
218
1.10
0.14
1.3
1.4
—
—
—
0
0
38
407
0.93
0.13
1.4
1.4
—
—
—
0
0
36
339
1.07
0.10
1.5
1.3
258.7
258.0
miu/ml
0.00
14
169
77
798
0.96
0.10
1.4
1.5
—
—
—
0
0
5
44
1.14
0.10
2.6
1.4
—
—
—
0
0
6
56
1.07
0.08
3.7
1.7
—
—
—
0
0
29
308
0.94
0.08
1.3
1.5
—
—
—
0
0
30
283
1.06
0.08
2.6
2.4
—
—
—
0
0
39
409
0.95
0.08
1.4
1.4
—
—
—
0
0
39
409
0.95
0.08
1.4
1.4
—
—
—
0
0
39
409
0.95
0.08
1.4
1.4
—
—
—
0
0
7
66
1.06
0.08
2.6
1.4
—
—
—
0
0
11
98
1.12
0.07
1.8
1.5
—
—
—
0
0
16
174
0.92
0.07
1.6
1.8
—
—
—
0
0
94
917
1.03
0.07
1.6
1.5
—
—
—
0
0
23
217
1.06
0.06
1.2
1.2
—
—
—
0
0
12
129
0.93
0.03
1.0
1.2
—
—
—
0
0
14
149
0.94
0.03
2.0
1.8
4.2
5.4
iu/l
—
6
57
15
147
1.02
0.00
1.5
1.1
—
—
—
0
0
45
449
1.00
0.00
1.4
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
15.0
—
—
—
0
0
9
90
1.00
0.00
1.1
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
481.1
—
0
9
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
7
69
1.01
0.00
1.0
1.6
—
11.5
—
0
11
9
91
0.99
0.00
1.6
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
4.8
—
0.3
—
0
6
0
8
0.00
0.00
0.0
7.1
—
17.0
—
0
8
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
7
69
1.01
0.00
1.1
1.1
—
—
—
0
0
5
50
1.00
0.00
1.6
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
26
260
1.00
0.00
1.8
1.9
0.4
0.6
ug/l
1.56
14
95
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: F5_READING – Disorders in reading
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).